Is Creative Medical Technology Holdings, Inc. (CELZ) a Buy, Sell, or Hold?
NASDAQ : CELZ
Creative Medical Technology Holdings, Inc.
$0.879 USD
$0.02 (2.21%)
- Volume
- 148.63K
- Average Volume
- 3.3M
- Market Capitalization
- $2.27M
- P/E Ratio
- -0.42
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $6.25
- Year Low
- $0.79
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $19.69
Company Overview
NASDAQ
Timothy Warbington
Biotechnology
Healthcare
CELZ
4
US
USD
Liquidity Metrics
0.00
19.69
19.69
18.60
0.00
Sales & Valuation
$6000
756.13
0.53
-0.41
-1.51
Profitability
-$2.52
-$6M
-192066.27%
-192020.93%
-88.50%
-89.46%
P/E Metrics
-0.42
-0.01
-0.01
Analyst Price Target & Rating
3/5
1 Analysts
%
Poll Results
About Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Stock
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility. ...
Creative Medical Technology Holdings Issues Mid-Year Update
2026-07-01 09:00:00
Highlights Significant Clinical, Regulatory, and Strategic Progress, Supported by a Disciplined Capital Allocation Strategy Highlights Significant Clinical, Regulatory, and Strategic Progress, Supported by a Disciplined Capital Allocation Strategy
2026-06-30 14:07:00
PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a biotechnology company dedicated to the advancement of regenerative therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedic, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-291713). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.5 million, before deducting financial advisory fees. Roth Capital Partners is acting as the Company's financial advisor for this transaction. In consideration for the immediate exercise of the existing warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 5,580,680 shares of common stock, at an exercise price of $1.60 per share upon the receipt of shareholder approval for a term of five years from the initial exercise date. The transaction is expected to close on June 30, 2026. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.
2026-06-22 09:15:00
PHOENIX, June 22, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expansion of the Company's FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel) for chronic lower back pain associated with degenerative disc disease.
Creative Medical Technology opens nationwide burn-pit data registry
2026-06-16 15:52:12
Creative Medical Technology Holdings Inc (NASDAQ:CELZ) has moved Project PHOENIX into a nationwide virtual data-collection phase, opening enrollment for a regulatory-approved registry that the company designed to support U.S. veterans exposed to burn pits and other toxic environmental hazards.
Creative Medical Technology opens nationwide burn-pit data registry
2026-06-16 11:49:00
Creative Medical Technology Holdings Inc (NASDAQ:CELZ) has moved Project PHOENIX into a nationwide virtual data-collection phase, opening enrollment for a...
2026-06-16 09:00:00
The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics
2026-04-28 09:01:00
Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market
Frequently Asked Questions
-
What is the current Creative Medical Technology Holdings, Inc. (CELZ) stock price?
-
Creative Medical Technology Holdings, Inc.(NASDAQ:CELZ) stock price is $0.879 in the last trading session. During the trading session, CELZ stock reached the peak price of $6.25 while $0.7901 was the lowest point it dropped to. The percentage change in CELZ stock occurred in the recent session was 2.21% while the dollar amount for the price change in CELZ stock was $0.02.
-
CELZ's industry and sector of operation?
-
The NASDAQ listed CELZ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CELZ?
-
Timothy Warbington | Co-Founder, Chairman, President & Chief Executive Officer
Donald Dickerson | Senior Vice President, Chief Financial Officer & Director
|
|
| -
How many employees does CELZ have?
-
Number of CELZ employees currently stands at 4. CELZ operates from 211 East Osborn Road, Phoenix, AZ 85012, US.
-
Link for CELZ official website?
-
Official Website of CELZ is: https://www.creativemedicaltechnology.com
-
How do I contact CELZ?
-
CELZ could be contacted at phone #480 399 2822 and can also be accessed through its website. CELZ operates from 211 East Osborn Road, Phoenix, AZ 85012, US.
-
How many shares of CELZ are traded daily?
-
The average number of CELZ shares traded daily for last 3 months was 3.3M.
-
What is the market cap of CELZ currently?
-
The market value of CELZ currently stands at $2.27M with its latest stock price at $0.879